Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Under the deal, Quiver will receive an undisclosed advance payment and research support
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
Nadda underlined that India’s policy framework is aligned with this transformation
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Subscribe To Our Newsletter & Stay Updated
